A pharmacokinetic drug–drug interaction study between rosuvastatin and emvododstat, a potent anti‐SARS‐CoV ‐2 ( COVID ‐19) DHODH (dihydroorotate dehydrogenase) inhibitor
Pharmacology Research & Perspectives · 2023
DOI: 10.1002/prp2.1076 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2023. Verfasst von Terri L Morton und 9 weiteren Autor:innen. Beteiligte Einrichtung: PTC Therapeutics, South Plainfield, New Jersey, USA. Hauptthemen laut MEDLINE: Dihydroorotate Dehydrogenase, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: PTC Therapeutics.
Abstract (Originalsprache)
A therapeutic agent that targets both viral replication and the hyper‐reactive immune response would offer a highly desirable treatment for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2; COVID‐19) management. Emvododstat (PTC299) was found to be a potent inhibitor of immunomodulatory and inflammation‐related processes by the inhibition of dihydroorotate dehydrogenase (DHODH) to reduce SARS‐CoV‐2 replication. DHODH is the rate‐limiting enzyme of the de novo pyrimidine nucleotide biosynthesis pathway. This drug interaction study was performed to determine whether emvododstat was an inhibitor of breast cancer resistance protein (BCRP) transporters in humans. Potential drug–drug interactions (DDIs) between emvododstat and a BCRP transporter substrate (rosuvastatin) were investigated by measuring plasma rosuvastatin concentrations before and after emvododstat administration. There was no apparent difference in rosuvastatin plasma exposure. The geometric means of maximum plasma rosuvastatin concentrations (C max ) were 4369 (rosuvastatin) and 5141 pg/mL (rosuvastatin + emvododstat) at 4 h postdose. Geometric mean rosuvastatin area under the concentration–time curve (AUC) from time 0 to the last measurable plasma concentration was 45 616 and 48 975 h·pg/mL when administered alone and after 7 days of b.i.d. emvododstat dosing, respectively. Geometric least squares mean ratios for C max and AUC were approximately equal to 1. Overall, administration of multiple doses of 100 mg emvododstat b.i.d. for 7 days in combination with a single dose of rosuvastatin was safe and well tolerated. Emvododstat can be safely administered with other BCRP substrate drugs. Hence, pharmacokinetic DDI mediated via BCRP inhibition is not expected when emvododstat and BCRP substrates are coadministered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PTC Therapeutics, South Plainfield, New Jersey, USA.
ORCID-Profile: Terri L Morton, Ronald Kong
Förderung
- PTC Therapeutics
Zitieren
APA
Morton, T. L., Laskin, O. L., Kaushik, D., Lee, L., Ma, J., Kristensen, A., O'Keefe, K., Golden, L., Klein, M., & Kong, R. (2023). A pharmacokinetic drug–drug interaction study between rosuvastatin and emvododstat, a potent anti‐SARS‐CoV ‐2 ( COVID ‐19) DHODH (dihydroorotate dehydrogenase) inhibitor. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.1076
Vancouver
Morton TL, Laskin OL, Kaushik D, Lee L, Ma J, Kristensen A, et al. A pharmacokinetic drug–drug interaction study between rosuvastatin and emvododstat, a potent anti‐SARS‐CoV ‐2 ( COVID ‐19) DHODH (dihydroorotate dehydrogenase) inhibitor. Pharmacology Research & Perspectives. 2023. doi:10.1002/prp2.1076
BibTeX
@article{Morton2023,
author = {Morton, Terri L and Laskin, Oscar L and Kaushik, Diksha and Lee, Lucy and Ma, Jiyuan and Kristensen, Allan and O'Keefe, Kylie and Golden, Lee and Klein, Matthew and Kong, Ronald},
title = {A pharmacokinetic drug–drug interaction study between rosuvastatin and emvododstat, a potent anti‐SARS‐CoV ‐2 ( COVID ‐19) DHODH (dihydroorotate dehydrogenase) inhibitor},
journal = {Pharmacology Research & Perspectives},
year = {2023},
doi = {10.1002/prp2.1076}
}
EUVIMED